Channel
@JAMAupdates
On this record: Topic · Growth · Engagement · Reactions · Posts · Citations · Telegram's recommendations · Cite this entry
16,527subscribers
+591 since we began measuring on 7 August 2026
Risers and fallers across the register · movement among entries of 10,000–31,623.
| Telegram ID | -1001468558420 |
|---|---|
| Type | Channel |
| Username | @JAMAupdates |
| Created | Between 1 April 2019 and 31 October 2021 — estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 7 August 2026 |
| Last confirmed live | 3 October 2026 |
| Measurements held | 34 |
| Confirmed unchanged | 1 time, most recently 3 October 2026 |
| On Telegram | t.me/JAMAupdates |
Health & wellness — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 10 September 2026 and assigned it the closest of 31 fixed categories, at 63% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 3 Oct 2026, 22:19 | 16,527 | +57 |
| 25 Sept 2026, 02:58 | 16,470 | +61 |
| 18 Sept 2026, 22:01 | 16,409 | +34 |
| 16 Sept 2026, 15:17 | 16,375 | +22 |
| 14 Sept 2026, 20:19 | 16,353 | +22 |
| 13 Sept 2026, 04:20 | 16,331 | +20 |
| 11 Sept 2026, 04:59 | 16,311 | +26 |
| 8 Sept 2026, 05:01 | 16,285 | +40 |
| 5 Sept 2026, 02:01 | 16,245 | +3 |
| 3 Sept 2026, 09:22 | 16,242 | +10 |
| 2 Sept 2026, 01:33 | 16,232 | +6 |
| 1 Sept 2026, 05:05 | 16,226 | +7 |
| 31 Aug 2026, 06:26 | 16,219 | +6 |
| 30 Aug 2026, 07:56 | 16,213 | +13 |
| 29 Aug 2026, 09:57 | 16,200 | +7 |
| 28 Aug 2026, 13:13 | 16,193 | +9 |
| 27 Aug 2026, 14:32 | 16,184 | +9 |
| 26 Aug 2026, 17:43 | 16,175 | +16 |
| 24 Aug 2026, 17:45 | 16,159 | +16 |
| 23 Aug 2026, 03:25 | 16,143 | first reading |
141 posts held, back to 3 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 54 pages of Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 141 posts for this entry, the most recent from 2 September 2026. An engagement rate over an empty window would be a number about nothing.
20 reactions across 19 posts, in 4 distinct kinds. The most used accounts for 85.0% of them.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| ❤ | 17 | 85.0% | |
| 👍 | 1 | 5.00% | |
| 👎 | 1 | 5.00% | |
| 🔥 | 1 | 5.00% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 21 of the 141 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 20 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 141 most recent posts we hold, published 3 August 2026 to 2 September 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
Multiple Giant Right Atrial Myxomas—the Carney Complex https://jamanetwork.com/journals/jamacardiology/fullarticle/2853792 This case report discusses a diagnosis of Carney complex type 1 after genetic testing of a male patient aged 36 years with multiple atrial myxomas, bilateral testicular calcification, and a history of recurrent skin masses since childhood.
Bilateral vs Single Internal Thoracic Artery Grafts https://jamanetwork.com/journals/jamacardiology/fullarticle/2853791 This secondary analysis of a randomized clinical trial evaluates 15-year outcomes among patients undergoing bilateral internal thoracic artery grafts vs single internal thoracic artery grafts.
Error in Results https://jamanetwork.com/journals/jamacardiology/fullarticle/2853793 The Original Investigation titled “Statin Eligibility According to Atherosclerotic Cardiovascular Disease Risk in the US,” published online August 20, 2025, and in the October 2025 issue was corrected to fix the analytic sample size reported in the results. The sample size was originally reported as 133.6 million; the correct value …
❤1
COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season https://jamanetwork.com/journals/jama/fullarticle/2853778 This Special Communication aims to identify and summarize the most recently published evidence evaluating the effectiveness and safety of US-licensed COVID-19 vaccines and report on the epidemiology of SARS-CoV-2 in the US.
Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season https://jamanetwork.com/journals/jama/fullarticle/2853779 This systematic review summarizes research published 2025 to 2026 on the effectiveness and safety of seasonal influenza vaccines in the US.
RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season https://jamanetwork.com/journals/jama/fullarticle/2853780 This systematic review summarizes evidence from recent randomized clinical trials and observational studies reporting on the effectiveness and safety of respiratory syncytial virus (RSV) vaccines and monoclonal antibodies, as well as the epidemiology of RSV in the US.
Respiratory Season Virus Vaccines https://jamanetwork.com/journals/jama/fullarticle/2853781 This Perspective describes the Vaccine Integrity Project, established in 2025 in response to concerns about the stability and integrity of US vaccine policy due to disruptions to the work of the Advisory Committee on Immunization Practices; outlines the process for the 2026-2027 evidence review; and summarizes key findings re…
Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy https://jamanetwork.com/journals/jamacardiology/fullarticle/2853497 This cohort study derives and validates disease-specific, prognostic, quantitative tricuspid regurgitation risk thresholds in transthyretin amyloid cardiomyopathy and compares their prognostic performance with current guideline definitions and the Tricuspid Valv…
Rethinking Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy https://jamanetwork.com/journals/jamacardiology/fullarticle/2853498 Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a common, treatable cause of heart failure, with 5% to 15% of patients thought to have heart failure with preserved ejection fraction diagnosed with amyloid cardiomyopathy. The transformation i…
ATTs in Patients With Non-AD Copathologies https://jamanetwork.com/journals/jamaneurology/fullarticle/2853597 This Viewpoint examines how clinicians should approach amyloid-targeting therapies in patients with Alzheimer disease and suspected copathologies, emphasizing individualized decision-making, current evidence gaps, and the need for prospective studies.
Tirofiban for Branch Atheromatous Disease–Related Stroke https://jamanetwork.com/journals/jamaneurology/fullarticle/2853598 This randomized clinical trial investigates whether the combination of tirofiban and aspirin safely reduces the risk of early neurological deterioration or new stroke for patients with branch atheromatous disease–related stroke within 48 hours of onset.
Treatment Discontinuation in MOGAD—One Size Does Not Fit All—Reply https://jamanetwork.com/journals/jamaneurology/fullarticle/2853599 In Reply We thank Kim and Kim for their thoughtful comments on our study published in JAMA Neurology and for emphasizing the need to better define treatment discontinuation strategies in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD).
Showing the 12 most recent of 141 posts we hold for @JAMAupdates. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Republishes
Channels on the register whose posts this channel has forwarded.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.
This channel appears in 50 seed channels' Telegram-generated recommendation lists in total, of which the 24 where it ranks highest are shown above. Each is Telegram’s list for THAT channel, not this one — see how this is measured.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 3 October 2026 — this entry's latest reading, not the date you are reading this.
“JAMA (Journal of the American Medical Association)” (@JAMAupdates), 16,527 subscribers as measured 3 October 2026. Telegram Register, tgregister.com/channel/JAMAupdates.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.